Tasly Pharmaceutical (SHA:600535) subsidiary Tasly Biopharma received China's regulatory approval to conduct clinical trials for its Pro-UK drug.
Approval was granted to conduct clinical trials for patients with acute ischemic stroke onset between 4.5 and 24 hours, according to a weekend filing with the Shanghai bourse.
Shares of the drug manufacturer closed 4% lower Monday.